17th Annual BIO CEO & Investor Conference to Feature Congressional Leaders, Institutional Investors, Industry Analysts and Senior Biotechnology Executives

BIO CEO Program to highlight latest in clinical development, timely policy perspectives and industry outlook for 2015

BIO CEO & Investor Conference 2015

WASHINGTON--()--The Biotechnology Industry Organization (BIO) today announces Business Roundtables, Plenary Sessions and Therapeutic Workshops selected for the 17th annual BIO CEO & Investor Conference. The event, to be held in New York City, February 9-10, 2015, is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

“Following another banner year for biotech equity returns as well as the highest number of FDA new drug approvals in nearly two decades, investor interest in the biotech sector continues to grow,” said BIO President and CEO Jim Greenwood. “The BIO CEO & Investor Conference will be an excellent opportunity for attendees to hear from biotech, pharma and Wall Street leaders as they discuss the legislative, therapeutic and business catalysts driving positive industry activity as well as their expectations for 2015 and beyond.”

The conference program will feature five Fireside Chats with leading biopharmaceutical executives and Wall Street analysts, each followed by an interactive question and answer session.

Fireside Chats include:

  • Ian C. Read, Chairman of the Board and CEO, Pfizer
    Tuesday, February 10, 3:30 – 4:25 pm
  • John F. Milligan, PhD, President and COO, Gilead Sciences
    Tuesday, February 10, 10:00 – 10:55 am
  • John Maraganore, PhD, CEO, Alnylam
    Tuesday, February 10, 11:00 – 11:55 am
  • Peter Greenleaf, CEO, Sucampo
    Tuesday, February 10, 1:30 – 2:25 pm
  • Ron Cohen, MD, President & CEO, Acorda
    Tuesday, February 10, 2:30 – 3:25 pm

Business Roundtables include:
Emerging Trends in Deal Structures
Monday, February 9, 9:30 – 10:25 am
Moderator: Effie Toshav, Partner, Fenwick & West
Panelists:

  • Bruce Booth, Partner, Atlas Venture
  • David H. Donabedian, PhD, Vice President, Head of Ventures & Early Stage Collaborations, AbbVie
  • C. Randall Mills, PhD, President and CEO, California Institute of Regenerative Medicine (CIRM)
  • Adelene Perkins, CEO, Infinity Pharmaceuticals
  • Mark Schoenebaum, MD, Senior Managing Director, Evercore ISI

How Industry Rates Interactions with the FDA: What is Working Well and What Needs to Improve?
Monday, February 9, 1:30 – 2:25 pm
Moderator: Cartier Esham, PhD, EVP Emerging Companies Section, BIO
Panelists:

  • Paul Hastings, Chairman and CEO, OncoMed Pharmaceuticals
  • Michael Narachi, President and CEO, Orexigen Therapeutics

Digital Health—Early Successes for Investors and Biotech R&D Productivity
Monday, February 9, 3:00 – 3:55 pm
Moderator: Matthew Hudes, U.S. Managing Principal, Biotechnology, Deloitte
Panelists:

  • Donald Jones, Co-Founder and Chairman, Wireless-Life Sciences Alliance; Chief Digital Officer of the Scripps Translational Science Institute
  • Julie Papanek, Principal, Canaan Partners
  • Ryan Pierce, Entrepreneur in Residence, Rock Health

Plenary Sessions include:
Producing "21st Century Cures"—2015 U.S. Legislative Outlook
Monday, February 9, 12:00 – 12:55 pm
Moderator: Jim Greenwood, President and CEO, BIO
Panelists:

  • Rep. Fred Upton, Chairman of Energy & Commerce Committee
  • Rep. Diana DeGette, Member of Energy & Commerce Committee

Following Venture Flow by Disease Indication—Past, Present, and Future Focus of VC Investment in Biotech
Tuesday, February 10, 12:00 – 12:55 pm
Moderator: Stephen B. Thau, Partner, Morrison Foerster
Panelists:

  • Roel Bulthuis, Vice President & Managing Director, MS Ventures
  • Jean-Francois Formela, MD, Partner, Atlas Venture
  • Robert Kiss, Managing Director, JP Morgan Investment Management
  • Jonathan Leff, Partner, Chairman of the Deerfield Institute, Deerfield
  • David Thomas, Director, Industry Research & Policy Analysis, BIO

“What’s Liquidity Got to Do With It?”—2015 Market Outlook
Tuesday, February 10, 4:30 – 5:25 pm
Moderator: Annette Grimaldi, Managing Director, Healthcare Life Sciences, BMO Capital Markets
Panelists:

  • Darren Carroll, SVP of Corporate Business Development, Eli Lilly and Company
  • John Chambers, Vice-Chairman and Head of Healthcare Investment Banking, Roth Capital Partners
  • Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital
  • Mark Timney, President & CEO, Purdue Pharma

Therapeutic Workshops include:
Personalizing Oncology Treatments with Molecular Diagnostics
Monday, February 9, 8:00 – 8:55 am
Moderator: Michael King, Managing Director, Senior Research Analyst, JMP Securities
Panelists:

  • Arie Belldegrun, MD, FACS, Chairman, President & CEO, Kite Pharma
  • Jean C. Zenklusen, PhD, Director, The Cancer Genome Atlas, National Institutes of Health

Getting Ahead of Ebola and Other Infectious Threats—Overturning Assumptions
Monday, February 9, 11:00 – 11:55 am
Moderator: Phyllis Arthur, Senior Director, Vaccines, Immunotherapeutics & Diagnostics Policy, BIO
Panelists:

  • Ripley Ballou, MD, Head of Ebola Vaccine Research, GSK
  • Chris Garabedian, President & CEO, Sarepta Therapeutics
  • Peter Khoury, PhD, Senior Program Officer, Bill & Melinda Gates Foundation
  • Guillaume Leroy, PhD, Head of Dengue Vaccines, Sanofi Pasteur
  • Clifford J. Stocks, CEO, Theraclone Sciences

“Trust Your Gut”—Therapeutic Opportunities of the Microbiome
Tuesday, February 10, 8:00 – 8:55 am
Moderator: Mark Breidenbach, PhD, Equity Research Group, H.C. Wainwright & Co.
Panelists:

  • Karim Dabbagh, PhD, Chief Scientific Officer, Second Genome
  • Jeffrey Riley, CEO & President, Synthetic Biologics

To register now or learn more about the BIO CEO & Investor Conference, including program and partnering information, plus the names of more than 150 presenting companies, please visit here.

Complimentary investor registration is available for those who qualify. For information regarding qualified investor criteria and to apply for investor registration, please visit here.

Media registration is complimentary for credentialed members of the media. All registrations are subject to verification of credentials.

BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors including Double Helix Sponsor Merck, Helix Sponsors Eli Lilly and Pfizer, and Supporting Bank Sponsors BMO Capital Markets, HC Wainwright & Co., JMP Securities, Lazard and ROTH Capital Partners, LLC.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events

BIO CEO & Investor Conference
February 9-10, 2015
New York City, NY

BIO-Europe Spring
March 9-11, 2015
Paris, France

BIO Asia International Conference
March 24-25, 2015
Tokyo, Japan

BioEquity Europe
May 19-20, 2015
Vienna, Austria

BIO International Convention
June 15-18, 2015
Philadelphia, PA

Contacts

Biotechnology Industry Organization
Abigail Hirsch, 202-962-9235
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech

Contacts

Biotechnology Industry Organization
Abigail Hirsch, 202-962-9235
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech